Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies (Q39375733)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies |
scientific article |
Statements
1 reference
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies (English)
1 reference
W Hester Visser
1 reference
Paul Winner
1 reference
Kim Strohmaier
1 reference
Meghan Klipfel
1 reference
Yahong Peng
1 reference
Kathleen McCarroll
1 reference
Roger Cady
1 reference
Donald Lewis
1 reference
Robert Nett
1 reference
Rizatriptan Protocol 059 and 061 Study Groups
1 reference
1 October 2004
1 reference
1 reference
44
1 reference
9
1 reference
891-899
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference